QuickView: Aramchol cleared to start key NASH trial
Galmed’s aramchol is expected to start a Phase IIb study in late 2014 for non-alcoholic steatohepatitis (NASH), an area that has attracted significant investor interest. Over the long term, further NASH studies as well as in non-alcoholic fatty liver disease (NAFLD), cholesterol gallstones and lipodystrophy are also planned. Although aramchol is unlikely to be near first-to-market, data seen to date suggest a competitive market profile.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.